Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction. BRS have had some issues in clinical trials not being able to match the performance of standard metallic drug eluting stents (DES) because of their thick stent struts. Newer generation BRS are in development with struts smaller than 100 micros, with will be closer to those of current generation metallic stents

 

News | Stents Bioresorbable

July 11, 2016 — University Hospitals Case Medical Center, Cleveland, is among the first in the country – and the first ...

Home July 11, 2016
Home
Technology | Stents Bioresorbable | Dave Fornell

July 5, 2016 — The U.S. Food and Drug Administration (FDA) has cleared the first fully bioresorbable coronary stent for ...

Home July 05, 2016
Home
News | Stents Bioresorbable

June 6, 2016 — Amaranth Medical announced that it completed enrollment in May in the RENASCENT-II study of its novel ...

Home June 06, 2016
Home
News | Stents Bioresorbable

May 17, 2016 — Biotronik presented 12-month data from the BIOSOLVE-II trial during a Hotline Session at EuroPCR 2016 ...

Home May 17, 2016
Home
Feature | Stents

May 16, 2016 — Cardinal Health announced it has entered into a distribution agreement with Biosensors that enables ...

Home May 16, 2016
Home
Absorb, bioresorbable stents
Feature | Stents Bioresorbable | Dave Fornell

Bioresorbable stents have been one of the hottest new cardiovascular technologies discussed at cardiology meetings over ...

Home April 13, 2016
Home
Videos | Stents Bioresorbable

Gregg Stone, M.D., director of cardiovascular research and education at Columbia University Medical Center / New York ...

Home April 12, 2016
Home
Abbott, Absorb bioresorbable stent, BVS, FDA advisory panel approval
Feature | Stents Bioresorbable | Dave Fornell

March 15, 2016 — An independent panel of experts convened by the U.S. Food and Drug Administration (FDA) voted 9 to 0 ...

Home March 15, 2016
Home
News | Stents Bioresorbable

March 11, 2016 — Magnesium Elektron, developer, manufacturer and supplier of high-performance magnesium alloys ...

Home March 11, 2016
Home
Blog

At the beginning of each year, I always try to determine what the next big cardiovascular technology advances to watch ...

Home January 20, 2016
Home
News | Cath Lab | Dave Fornell

The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel is set to review data and offer ...

Home January 20, 2016
Home
Blog | Cath Lab

For the past few years, the focus of the annual Transcatheter Cardiovascular Therapeutics (TCT) meetings has been on ...

Home November 05, 2015
Home
Videos | TCT

DAIC Editor Dave Fornell offers his choices for the most innovative new interventional cardiovascular technologies ...

Home November 05, 2015
Home
Videos | TCT

Tom Watson, clinical analyst for MDBuyLine, and DAIC Editor Dave Fornell discuss some of the new cardiovascular and ...

Home November 05, 2015
Home
News | Stents Bioresorbable

October 30, 2015 — Results from a clinical trial showed that that the Abbott Absorb everolimus-eluting bioresorbable ...

Home October 30, 2015
Home
Subscribe Now